MMJ PhytoTech Ltd (ASX:MMJ) MediPharm Labs Enters Contract with Emerald (CVE:EMH)

Perth, Oct 11, 2018 AEST (ABN Newswire) - MMJ PhytoTech Limited (ASX:MMJ) (OTCMKTS:MMJJF) ("MMJ") is pleased to attach a release from MediPharm Labs Inc ("MediPharm Labs") (TSX-V: LABS) announcing that it has entered into a Cannabis Concentrate Program Agreement with Emerald Health Therapeutics Inc ("Emerald") (CVE:EMH).

MMJ has CAD$5 million of equity invested in MediPharm Labs with 5.88 million shares (CAD$0.85 cost per share) and 2.94 million warrants (exercisable at CAD$1.20 per share by October 2020).

To view the release, please visit:
http://abnnewswire.net/lnk/F8RY7W5L


About MMJ Group Holdings Ltd

MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: http://www.mmjphytotech.com.au/investors/

   

Related Companies

MMJ Group Holdings Ltd   
Emerald Health Therapeutics Inc